Oculis announces publication of positive Phase 2 data in Translational Vision Science & Technology (TVST) investigating topical anti-TNFα agent Licaminlimab (OCS-02) in acute anterior uveitis. ... 22 November, 2022
Oculis Strengthens its Scientific Advisory Board with World-Leading Ophthalmology Experts to Support Pipeline Development 03 November, 2022
Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology 17 October, 2022
Oculis announces publication and presentation of Phase 2 data showing topical OCS-01 improves macular thickness and visual acuity in patients with diabetic macular edema 06 September, 2022
Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFα agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease 23 August, 2022
First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 for Inflammation and Pain following Cataract Surgery 29 June, 2022
Oculis Strengthens Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma 02 March, 2022
Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China) 05 January, 2022
Oculis Announces Patient Dosing in its First Phase 3 (DIAMOND Study – DIAbetic Macular edema patients ON a Drop) with OCS-01, a Novel, Investigational Topical Eye Drop Treatment for Diabetic Macular Edema (DME) 12 November, 2021
